Movement Disorders

Papers
(The median citation count of Movement Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
332
May Infographic236
Movement Disorders: Volume 40, Number 6, June 2025165
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease162
Movement Disorders: Volume 40, Number 2, February 2025120
Issue Information111
John Michael Walshe (April 24, 1920–October 14, 2022)111
In Memoriam Mahlon R. DeLong (1938–2024)110
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism109
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?108
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 1296
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia86
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?85
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers80
Assessing Intronic Variable Number Tandem Repeat ( VNTR) Expansions of the HSF1 78
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank77
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy75
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy68
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model68
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals68
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease67
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease65
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in H65
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulati65
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property63
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia63
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure61
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials59
Multimodal Imaging Investigation of the Dentato‐Thalamo‐Cortical Pathway in Friedreich's Ataxia59
A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase 57
Indirect Striatal Projection Neurons Drive a D2 Receptor‐Dependent Pathway to Dyskinesia and Dystonia56
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation53
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease53
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism53
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment52
Rapid Eye Movement Sleep Behavior Disorder with Clinical Dementia with Lewy Bodies Phenotype but Lacking Postmortem Central Nervous System Synuclein Pathology: Alternate Etiologies52
Friedreich's Ataxia in Colombia: A Population‐Based Study of Incidence and Socioeconomic Determinants50
Clinical Outcome Assessments for Functional Performance in Spastic Paresis: Systematic Review, Critique, and Recommendations49
The Lows of High Reward: Choking Under Pressure48
Compound Heterozygous Structural Variants in Cases with Unsolved PRKN ‐Associated Parkinson's Dise48
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease48
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”47
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search47
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease46
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and 18F‐Fluorodopa‐Positron Emission Tomography46
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank46
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity46
Brain–Computer Interface Improves Symptoms of Isolated Focal Laryngeal Dystonia: A Single‐Blind Study46
Author Index45
Functional Movement Disorders and Drug‐Induced Movement Disorders43
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation43
A CGG Repeat Expansion in CSNK1E Associated wit42
41
Thank you to Reviewers 202240
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”40
Issue Information40
Issue Information40
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy38
Obituary for Jan O. Aasly (1950–2022)38
Research Priorities on the Role of α‐ Synuclein in Parkinson's Disease Pathogenesis38
Movement Disorders: Volume 37, Number 9, September 202238
[ 11 C ]( R )‐ 38
38
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder37
Neurodevelopmental Disorder and Cortical Myoclonus in ZMYM2 Deficiency37
Author Response to Comment on “Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations”36
Movement Disorders Thanks Journal Reviewers from 202536
Apolipoprotein E Polymorphism Is Associated with Age of Onset and Neuropathology in Colony Stimulating Factor 1 Receptor‐Related Disorder36
Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort36
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies36
Dystonia35
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation35
AI, Technology, Telemedicine35
STUB1 ( SCA48 )/ 35
Erratum to “Paired deep brain stimuli elicit short‐term facilitation in globus pallidus interna and subthalamic nucleus”34
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine34
Genetic Variation Analysis of Essential Tremor: Insights from the China Essential Tremor Alliance Cohort33
Safeguarding Advanced Therapies—The Dangers of Therapeutic Neuroabandonment: How Should We Ensure Patient Safety and Scientific Integrity When a Commercial Clinical Trial Sponsor Becomes Insolvent?33
Bilateral Globus Pallidus Deep Brain Stimulation Improves Motor Function in ADCY5 ‐Related Disorde33
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy32
Substantiating the Short Burst Duration in Cortical Myoclonus32
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial32
18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies32
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease32
Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease31
Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism31
In Memoriam Gregor K. Wenning (1964–2024)31
Movement Disorders: Volume 38, Number 12, December 202330
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”30
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease29
Keyword Index29
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia28
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid28
Issue Information28
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure28
February Infographic28
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release28
Movement Disorders: Volume 40, Number 3, March 202528
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients28
Issue Information27
Parkinsonisms27
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”27
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy27
Issue Information27
August Infographic27
Education, History, Disparities, Other Topics26
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease26
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models26
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia26
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis26
GAA ‐ FGF14 Expansions and 26
Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy26
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”26
Pain in Multiple System Atrophy: A Community‐Based Survey26
Target‐Dependent Postoperative Weight Gain after Pallidothalamic Tractotomy versus Pallidotomy for Dystonia25
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?25
Unilateral Magnetic Resonance‐Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain T25
COVID ‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism25
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial25
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease25
Levodopa Disrupts Activity Patterns and Encoding of Movement in Striatal Cholinergic Interneurons of Behaving Mice25
Deciphering the Janus‐Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis25
Defining the Importance of Minor Hallucinations in Parkinson's Disease25
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review24
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)24
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia24
Pallidal Evoked Resonant Neural Activity as a Candidate Biomarker for Deep Brain Stimulation in Dystonia24
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders24
Correction to “Evaluation of Induced Pluripotent Stem Cell‐Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism”24
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease24
Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism24
Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease24
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration24
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review24
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review24
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease24
Movement Disorders: Volume 38, Number 9, September 202323
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?23
23
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings23
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease23
February Infographic23
Issue Information23
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”23
Automated Motor Tic Detection: A Machine Learning Approach23
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome23
Obituary for Professor Hiroshi Shibasaki23
Learning to Have a Long‐Duration Response23
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase23
Patient‐Derived Neurons Exhibit α‐Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial22
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study22
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis22
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers22
Movement Disorders: Volume 39, Number 9, September 202422
Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning22
Natural Killer Subset Changes and Vascular Endothelial Growth Factor‐A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study22
September Infographic22
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study22
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration22
Reply to “Comments on ‘Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets’”22
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia22
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum22
Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B22
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease22
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?21
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification21
Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT ‐02287 Administration in Healthy Volunteers21
Reply to: “Refutation of the αSyn ‐ SAA ‐Based Staging for Parkinson's Progression (Neuronal α‐Syn21
Reply to: “Alcohol Intake and Parkinson's Symptoms Following Diagnosis”21
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease21
Beyond the Homunculus— SCAN ‐ AMN as a Shared Action‐Oriented Neural Substrate across Movement Dis21
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease21
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D ‐Video: Evaluation of Sinusoidality and Rhythmicity21
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels21
The Global Parkinson's Disease Genetics ( GP2 ) Genome Browser21
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts21
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease21
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes20
20
Movement Disorders: Volume 38, Number 11, November 202320
Prasinezumab: A Bayesian Perspective on Its Efficacy20
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial20
20
April Infographic20
Issue Information20
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut20
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 202520
20
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R120
Keyword Index20
March Infographic20
Catatonia: What Else Matters?19
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons19
Clinical Trials in GBA1 ‐Associated Parkinson's Disease: A Need for Molecular Classification19
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients19
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor19
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results19
Reply to: “Unravelling the Complexity of VPS16 Splicing: Clinical Implications and Unresolved Ques19
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease19
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial19
Respiratory Function in Friedreich's Ataxia19
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception19
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study18
Functional Magnetic Resonance Imaging (f MRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies18
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor18
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease18
Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study ( iCARE ‐ PD18
Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease18
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia18
Reply to “Prevalence of NOTCH2NLC and FMR1 18
Atypical and Other Parkinsonisms18
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?18
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review18
The Race to Salvage Glucocerebrosidase: Understanding Small‐Molecule Therapies for GBA1 ‐Associate18
Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism C18
The Impact of Calcitriol on Frataxin Levels in Friedreich's Ataxia Patients: Insights and Future Directions18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques18
Reply to: Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy18
Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine Monkey Model of Parkinson's Disease17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia17
Dysautonomia Is Associated with Cognitive Fluctuation in Dementia with Lewy Bodies17
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?17
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease17
Surgery Imaging and Technology17
Advancing Parkinson's Research: Considerations and Future Directions17
Movement Disorders: Volume 40, Number 7, July 202517
Pathophysiological Role of Primary Motor Cortex in Essential Tremor17
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study17
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China17
Aggregation‐Seeding Forms of α‐Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid17
The CM ‐ aGPi Network in the Generation of Tics in Tourette Syndrome16
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD16
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”16
Top Movement Disorders Journal Reviewers from 202416
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease16
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism16
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family16
Reply to: “Letter to the Editor by Cao et al.”16
A GNAI1 Pathogenic Variant in a Case with GNAO1‐Isolated Dystonia: A Modifier of Disease Severity?16
Neurodevelopmental Gene‐Related Dystonia‐Parkinsonism with Onset in Adults: A Case with NAA15 Variant16
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome16
Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis16
Further Directions in Mindfulness‐Based Interventions for Tic Disorders16
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease16
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts16
Actor or Observer: The Sensorimotor Striatum Shapes Motor Output for Learned but Not Innate Motor Tasks15
Comments on: “Biallelic ELOVL1 Variants Are Linked to Hypomyelinating Leukodystrophy, Movement Disorder, and Ichthyosis”15
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study15
Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease15
1.3392379283905